IQVIA Holdings Inc. Share Price Target ‘$276.35’, now 17.4% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

IQVIA Holdings Inc. which can be found using ticker (IQV) have now 17 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $300.00 and $235.00 with the average share target price sitting at $276.35. (at the time of writing). Given that the stocks previous close was at $235.48 this would indicate that there is a potential upside of 17.4%. It’s also worth noting that there is a 50 day moving average of $244.78 and the 200 moving average now moves to $220.45. The company has a market cap of 42.19B. The stock price for the company is currently $231.77 USD

The potential market cap would be $49,507,095,510 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/E ratio of 31.75, revenue per share of $81.52 and a 4.98% return on assets.

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search